An interventional study of Rectal Indomethacin and Prophylactic Pancreatic duct stenting in Post-ERCP Acute Pancreatitis, sponsored by Moti Lal Nehru Medical College. Recruiting at 2 sites in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-06-28.
Sponsored by Moti Lal Nehru Medical College · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing indomethacin in Pancreatitis — 6 open to participants now, 6 under way, 1 of them phase 3. Indomethacin · Pancreatitis.
Among the 20 studies testing indomethacin in Pancreatitis, this one is the 12th largest by planned enrollment, is the only one that started in 2023, is one of 6 with no phase, and was the 15th registered.
558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.
Browse Pancreatitis studies →6 of the 20 studies testing indomethacin in Pancreatitis are open now, in 5 countries. Recruiting first, the newest first:
Changhai Hospital · Sites in China
Ages 18+
Air Force Military Medical University, China · Sites in China
Ages 18–90
Peking Union Medical College Hospital · Sites in China
Ages 18–80
Chinese University of Hong Kong · Sites in China, Hong Kong, Thailand
Ages 18–99
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
Indomethacin: first FDA approval 1965 (INDOCIN). What it is approved for, and how studies give it, is on its page →
Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 7 · Phase 4 7
First in 2005; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 384 is above the median of 100 across 349 interventional studies indexed under Pancreatitis.
Median enrollment 492 across the 20 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 20 has an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Moti Lal Nehru Medical College as lead sponsor.
Moti Lal Nehru Medical College has 1 study filed under Pancreatitis — fewer than ten, so there is no comparison to draw.
1 of the studies testing indomethacin in Pancreatitis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07071441Air Force Military Medical University, ChinaIndomethacin vs Diclofenac for Preventing PEP | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing indomethacin in Pancreatitis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to compare rectal indomethacin alone versus combined pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis. The main question it aims to answer is: whether rectal indomethacin alone is superior to combination of pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis Participants will be patients who give consent to the study and who are required to undergo ERCP as part of their standard care.
If there is a comparison group: Researchers will compare [rectal indomethacin alone versus combined pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis.] to see if [whether rectal indomethacin alone is superior to combination of pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis].
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least 2 of the followings including
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Rectal Indomethacin
Procedure: Prophylactic Pancreatic duct stenting
Prophylactic Rectal indomethacin 100mg for prevention of post ERCP pancreatitis
Prophylactic pancreatic duct stenting with rectal indomethacin 100 mg for prevention of post-ERCP pancreatitis
Also known as: Rectal indomethacin 100 mg
To compare rectal indomethacin alone versus combined pancreatic duct stent and rectal indomethacin in prevention of post ERCP pancreatitis
For comparison between these two arms the investigators will measure serum amylase in U/L value after 6 hour and 24 hour of the ERCP procedure. The investigators will also assess for pain abdomen and vomiting suggestive of acute pancreatitis.
Time frame: 24 hour
Plan to share: No
No publications or documents are linked to this record.
Started May 2023 (actual). Primary completion is estimated for May 2024, 11 months after the start.
Of 92 non-industry interventional studies with no phase under Pancreatitis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 11 months is below that.
Counting every sponsor, half of 95 studies reached it within 32 months; a quarter within 23 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Indomethacin